Anne-Marie Carbonell, MD

Dr. Anne-Marie Carbonell received her MD from St. Louis University (AOA, 1st in class) and trained in neurosurgery at the Cleveland Clinic. Prior to OncoSynergy, she gained valuable experience at MicroVention®, where she led pivotal trials at 35 clinical sites ultimately leading to FDA approval of 2 intracranial stents for treatment of brain aneurysms. At OncoSynergy, she translated decades of bench work into a manufactured product and successfully led FDA IND approval for our lead indication, glioblastoma. Leveraging her unique dual perspective as a clinician and patient Dr. Carbonell will lead OncoSynergy into a Phase 1 trial Q4 2020. Dr. Carbonell's goal is to keep OncoSynergy at the forefront of translational science, medicine and technology. She does so in part through her role as Principal Investigator on 2 active NIH grants, through active involvement in the Society of Neuro-oncology, and as a Sr. Healthcare & Pharmaceutical Advisor to Ever Network (a Digital Health Company).